Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125292763 | 12529276 | 3 | F | 20160515 | 20160718 | 20160705 | 20160726 | EXP | CN-ASTRAZENECA-2016SE71413 | ASTRAZENECA | 70.00 | YR | F | Y | 0.00000 | 20160726 | CN | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125292763 | 12529276 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | 820 | UG | 21773 | 10 | UG | SUSPENSION FOR INJECTION IN PRE-FILLED PEN | BID | |||||
| 125292763 | 12529276 | 2 | C | NOVORAPID | INSULIN ASPART | 1 | 0 | ||||||||||||
| 125292763 | 12529276 | 3 | C | LANTUS | INSULIN GLARGINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125292763 | 12529276 | 1 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125292763 | 12529276 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125292763 | 12529276 | Blood glucose increased | |
| 125292763 | 12529276 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125292763 | 12529276 | 1 | 20160515 | 0 |